Northwest Biotherapeutics Inc financial data

Symbol
NWBO on OTC
Industry
Pharmaceutical Preparations
Location
4800 Montgomery Lane, Suite 800, Bethesda, MD
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 8.61 % -30%
Debt-to-equity -114 % -7.24%
Return On Equity 94.1 % -3.64%
Return On Assets -244 % +1.56%
Operating Margin -4.36K % -38.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.3B shares +12.4%
Common Stock, Shares, Outstanding 1.29B shares +12.3%
Entity Public Float 617M USD 0%
Common Stock, Value, Issued 1.29M USD +12.3%
Weighted Average Number of Shares Outstanding, Basic 1.26M shares +10.9%
Weighted Average Number of Shares Outstanding, Diluted 1.26M shares +10.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.34M USD -38.1%
Revenue from Contract with Customer, Excluding Assessed Tax 357K USD -12.1%
Research and Development Expense 31.8M USD +7.4%
General and Administrative Expense 32.9M USD +6.22%
Operating Income (Loss) -63.2M USD -7.87%
Net Income (Loss) Attributable to Parent -69.5M USD +9.61%
Earnings Per Share, Basic -0.08 USD/shares +11.1%
Earnings Per Share, Diluted -0.08 USD/shares +11.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.94M USD -51.8%
Assets, Current 5.19M USD -38.6%
Property, Plant and Equipment, Net 17.3M USD +3.41%
Operating Lease, Right-of-Use Asset 4.52M USD +12.5%
Goodwill 626K USD 0%
Other Assets, Noncurrent 374K USD +4.76%
Assets 29.3M USD -6.89%
Liabilities, Current 59.6M USD +21%
Operating Lease, Liability, Noncurrent 4.83M USD +16.8%
Liabilities 93.6M USD +35.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -29K USD -101%
Retained Earnings (Accumulated Deficit) -1.42B USD -5.55%
Stockholders' Equity Attributable to Parent -80.1M USD -14.4%
Liabilities and Equity 29.3M USD -6.89%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.4M USD -10.4%
Net Cash Provided by (Used in) Financing Activities 12.1M USD -3.95%
Net Cash Provided by (Used in) Investing Activities -239K USD +82.1%
Common Stock, Shares Authorized 1.7B shares 0%
Common Stock, Shares, Issued 1.29B shares +12.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 352K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.94M USD -51.8%
Deferred Tax Assets, Valuation Allowance 261M USD +5.56%
Deferred Tax Assets, Gross 261M USD +5.56%
Operating Lease, Liability 5.08M USD +12.9%
Depreciation 400K USD +33.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -74.3M USD +8.66%
Lessee, Operating Lease, Liability, to be Paid 10.3M USD +7.9%
Operating Lease, Liability, Current 256K USD -30.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 886K USD +45.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 929K USD +14%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.24M USD +3.46%
Lessee, Operating Lease, Liability, to be Paid, Year Three 696K USD +14.1%
Deferred Tax Assets, Operating Loss Carryforwards 212M USD +4.45%
Preferred Stock, Shares Authorized 100M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 696K USD +14.1%
Operating Lease, Payments 241K USD +7.11%
Share-based Payment Arrangement, Expense 4.56M USD -15.5%
Interest Expense 5.73M USD +10.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%